Traws Pharma, Inc. 8-K Filing

Ticker: TRAW · Form: 8-K · Filed: Aug 14, 2025 · CIK: 1130598

Traws Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTraws Pharma, Inc. (TRAW)
Form Type8-K
Filed DateAug 14, 2025
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Traws Pharma, Inc. (ticker: TRAW) to the SEC on Aug 14, 2025.

How long is this filing?

Traws Pharma, Inc.'s 8-K filing is 3 pages with approximately 854 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-08-14 07:01:17

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K (this "Current Report") regarding the Earnings Release is incorporated by reference into this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 14, 2025, Traws Pharma, Inc. (the "Company") issued a press release (the "Earnings Release") announcing its financial results for the quarter ended June 30, 2025, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference. Additionally, on August 14, 2025, the Company began using a new corporate presentation. A copy of that corporate presentation is furnished as Exhibit 99.2 hereto and incorporated herein by reference. The presentation will also be posted to the Company's website. The information set forth under Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

Forward-Looking Statements This Current Report, including Exhibits 99.1 and 99.2, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes," "will" and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report,

Forward-looking statements in this Current Report, including Exhibits 99.1 and 99.2, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company's business and the accuracy of the forward-looking statements contained herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 14, 2025. 99.2 Investor Presentation, dated August 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.